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Aim: Although postprandial hyperglycemia is recognized as an important target in type 2
diabetes treatment, information on the prevalence of postprandial hyperglycemia through-
out the day is limited. Therefore, we assessed the prevalence of hyperglycemia throughout
the day in type 2 diabetes patients and healthy controls under standardized dietary, but
otherwise free-living conditions.
Methods: 60 male type 2 diabetes patients (HbA1c 7.5  0.1% [58  1 mmol/mol]) and 24 age-
and BMI-matched normal glucose tolerant controls were recruited to participate in a com-
parative study of daily glycemic control. During a 3-day experimental period, blood glucose
concentrations throughout the day were assessed by continuous glucose monitoring.
Results: Type 2 diabetes patients experienced hyperglycemia (glucose concentrations
>10 mmol/L) 38  4% of the day. Even diabetes patients with an HbA1c level below 7.0%
(53 mmol/mol) experienced hyperglycemia for as much as 24  5% throughout the day.
Hyperglycemia was negligible in the control group (3  1%).
Conclusion: Hyperglycemia is highly prevalent throughout the day in type 2 diabetes
patients, even in those patients with a HbA1c level well below 7.0% (53 mmol/mol). Standard
medical care with prescription of oral blood glucose lowering medication does not provide
ample protection against postprandial hyperglycemia.
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hyperglycemia is being considered a main target for type 2
diabetes treatment.
Although the European Association for the Study of
Diabetes, the International Diabetes Federation and the
American Diabetes Association have set stringent target
values for postprandial blood glucose control [9–11], most
practitioners and clinicians solely rely on blood HbA1c and
fasting plasma glucose concentrations to evaluate and adjust
therapeutic strategies. This is not surprising as HbA1c and
fasting glucose levels are easy to measure and both have been
extensively investigated. However, information on the preva-
lence of postprandial hyperglycemia is rather limited. Con-
ventional or surrogate markers of postprandial
hyperglycemia, such as self-monitored blood glucose or
post-challenge plasma glucose concentrations do not provide
true insight in the daily prevalence of hyperglycemia. In fact,
with the introduction of the latest generation continuous
glucose monitoring systems (CGMSs), previously undetected
glycemic excursions appear common in type 2 diabetes
patients [12,13]. However, inter- and intra-individual variation
in diet composition, timing and frequency of food intake, and
the level and distribution of habitual physical activity
complicate the interpretation of the glucose profiles provided
by these ambulatory glucose profiles. To accurately assess the
prevalence of hyperglycemia within subjects, between sub-
jects and/or between groups, appropriate standardization of
dietary intake is warranted.
In the present study, we evaluated daily glycemic control in
type 2 diabetes patients (n = 60) and healthy, normal glucose
tolerant controls (n = 24) under strict dietary standardization,
but otherwise free living conditions. This study provides more
insight in the daily prevalence of hyperglycemia in type 2
diabetes patients under standard medical care.
2. Methods
2.1. Subjects
A total of 60 male type 2 diabetes patients and 24 age- and BMI-
matched healthy, normal glucose tolerant controls were
recruited by advertisements in the local newspaper. Both
control subjects and type 2 diabetes patients in this study were
recruited as part of a larger project investigating the impact of
lifestyle intervention on glycemic control. Exclusion criteria
were renal failure, liver disease, morbid obesity (BMI > 40 kg/
m2), history of severe cardiovascular problems (myocardial
infarct in last year, stroke), hypertension (>160 mmHg systolic
or >100 mmHg diastolic), and exogenous insulin therapy. All
subjects were informed about the nature and the risks of the
experimental procedures before their written informed consent
was obtained. The Medical Ethical Committee of the Maastricht
University Medical Centre approved all clinical experiments.
2.2. Medication
Type 2 diabetes patients were treated with either oral blood
glucose lowering medication (metformin combined with
sulfonylurea derivatives [SUD] and/or thiazolidinediones[TZD], n = 30; metformin, n = 21; SUDs, n = 5; or TZDs n = 1)
or dietary modulation only (n = 3). All subjects had been on
stable medication and/or dietary prescription for at least 3
months before being recruited. Blood glucose lowering
medication was withheld 2 days prior to the screening but
continued as usual throughout the entire experimental period.
None of the control subjects were using any medication
known to interfere with the glucose metabolism.
2.3. Screening
Before selection into the study, all subjects performed an oral
glucose tolerance test (OGTT). After an overnight fast, subjects
arrived at the laboratory at 08:00 by car or public transporta-
tion. A fasting blood sample was obtained, after which a bolus
of 75 g glucose (dissolved in 250 mL water) was ingested (t = 0).
Venous blood samples were collected every 30 min until
t = 120. Plasma glucose concentrations were measured to
determine normal glucose tolerance and/or type 2 diabetes
according to ADA criteria [9]. Furthermore, HbA1c content was
determined in basal blood samples. Venous plasma glucose
and insulin concentrations obtained during the OGTT were
used to assess pancreatic b-cell function and insulin sensitiv-
ity. These parameters were assessed using the updated
homeostasis model assessment HOMA [14], and the oral
glucose insulin sensitivity (OGIS)-index [15], respectively.
2.4. Study design and protocol
The present study is a comparative study of daily glycemic
control in normal glucose tolerant subjects and type 2 diabetes
patients. During a 3-day experimental period, blood glucose
concentrations throughout the day were assessed by ambula-
tory continuous glucose monitoring. Subjects were studied
under standardized dietary, but otherwise free-living condi-
tions. On the first day of the assessment period, subjects
reported to the laboratory in the afternoon and were given
instructions regarding the standardized diet and the proper use
of the food intake and physical activity questionnaires. All
subjects received a short training in the use of the capillary
blood sampling method (Glucocard X Meter, Arkray Inc, Kyoto,
Japan). Next, a microdialysis fiber (Medica, Medolla, Italy) was
inserted in the peri-umbilical region. The micro-fiber was
subsequently connected to a portable continuous glucose-
measuring device (GlucoDay1S, A. Menarini Diagnostics, Fire-
nze, Italy). The continuous glucose monitoring system is based
on microdialysis principle and allows continuous glucose
monitoring for up to 48 h [16]. The glucose sensor, consisting
of immobilized glucose oxidase, measures the glucose concen-
tration every min and stores an average value every 3 min for up
to a 48 h period. The efficacy and the accuracy of the Gluco-
Day1S have been validated for both type 2 diabetic subjects
[16,17] and healthy subjects [18]. After placement of the
continuous glucose monitoring system, subjects were provided
with their diet after which they went home and resumed their
normal daily activities. Subjects consumed their designated
meals, drinks and snacks at the predetermined time-points.
Before consuming a meal, subjects obtained a capillary blood
glucose sample. The third day, subjects reported back to the
laboratory where the CGMS was removed.
Table 1 – Subjects’ characteristics.
Groups Control Type 2
diabetes
P value
n 24 60 NA
Age, year 58  1 59  1 0.22
Type 2 diabetes
diagnosis, year
NA 7  1 NA
Weight, kg 86.7  3.1 89.4  1.5 0.37
Height, m 1.78  0.01 1.76  0.01 0.12
BMI, kg/m2 27.3  0.9 28.8  0.4 0.13
FPGb, mmol/L 5.6  0.1 10.0  0.3 <0.001
Glucose OGTT 120 b,
mmol/L
4.8  0.2a 17.4  0.6a <0.001
HbA1c, % 5.6  0.1 7.5  0.1 <0.001
HbA1c, mmol/mol 38  1 58  1 <0.001
FPI b, mU/L 14.2  1.6 17.0  1.3 0.20
Insulin OGTT 120 b,
mU/L
45.2  10.5a 43.8  4.0a 0.87
HOMA-b% indexb 115  10 50  3 <0.001
HOMA-S% indexb 68  6 49  3 <0.001
OGIS indexb 396  10 264  6 <0.001
Oral glucose lowering
medication, No.
NA 57 NA
Metformin + SUD
and/or TZD, No.
NA 30 NA
Metformin only, No. NA 21 NA
SUD only, No. NA 5 NA
TZD only, No. NA 1 NA
Plus–minus data are expressed as means  SEM.
a Significant difference between fasting and postchallenge value
(P < 0.001).
b In the type 2 diabetes patients, glucose, insulin, HOMA and OGIS
index were determined from an OGTT performed after 2 days of
discontinuation of habitual use of oral blood glucose lowering
medication.
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All subjects maintained habitual physical activity patterns
throughout the entire experimental period, and refrained
from exhaustive physical labor and exercise training for at
least 3 days prior to and during the measurement period.
During the experimental period, subjects were provided with a
healthy, standardized diet, consisting of 3 meals and 3 snacks
per day. The diet was entirely composed of commercially
available food products. All meals and snacks were provided in
pre-weighed packages and ingested at pre-determined time-
points to ensure fully standardized diets during the 40 h test
period. The prescribed standardized diet was composed
according to the ADA dietary recommendations for type 2
diabetes [19] and provided on average 10.2  0.1 MJ/day,
consisting of 57 En% carbohydrate, 13 En% protein and 30
En% fat. The diet was designed to meet the energy require-
ments as calculated with the Harris and Bennedict equation
multiplied with a physical activity index level of 1.4.
2.6. Glycemic profile analysis
The acquired data from the continuous glucose monitor were
downloaded to a personal computer with GlucoDay1 software
(V3.0.5). Values reported by the CGMS were converted into
glucose values using the self monitored blood glucose values.
The glycemic profiles of the second day (from 07:00 to 07:00)
were used to determine average glucose levels, the prevalence
of hyperglycemia and the prevalence of hypoglycemia. Based
on the ADA/EASD guidelines for glycemic control [9,11], the
prevalence of hyperglycemia was defined as total time during
which glucose concentrations exceeded 10 mmol/L, and the
prevalence of hypoglycemia was defined as total time glucose
concentrations were below 3.9 mmol/L. These parameters
were determined over a 24 h time period, during daytime
(from 06:00 to 00:00) and overnight (from 00:00 to 06:00).
Additional analyses were performed specifically for the
subpopulation type 2 diabetes patients that achieved target
HbA1c levels below 7% (53 mmol/mol), according to ADA/EASD
targets for glycemic control [9,11].
2.7. Blood sample analysis
During the OGTT, blood samples (10 mL) were collected in EDTA
containing tubes and centrifuged at 1000 g and 4 8C for 10 min.
Aliquots of plasma were immediately frozen in liquid nitrogen
and stored at 80 8C until analyses. Plasma glucose concentra-
tions (Uni Kit III, Roche, Basel, Switzerland) were determined
with the COBAS FARA semi-automatic analyzer (Roche). Plasma
insulin concentrations were determined by radioimmunoassay
(HI-14K, Linco research Inc, St. Charles, USA). To determine
blood HbA1c content, 3 mL blood samples were collected in
EDTA containing tubes and analyzed by high-performance
liquid chromatography (Bio-Rad Diamat, Munich, Germany).
3. Statistics
Group comparisons were made by a two-tailed Student’s t-test
for unpaired observations. Time-dependent comparisonswithin subjects were performed using ANOVA for repeated
measurements followed by pairwise comparisons with Bon-
ferroni correction when applicable. Correlations between
variables were determined by Pearson’s correlation coeffi-
cient. Statistical comparisons were considered significant
when P values were <0.05. All statistical calculations were
performed using the SPSS 15.0.1.1 software package. HbA1c
values are reported in both NGSP (%) and IFCC (mmol/mol)
units. Unless otherwise specified, shown results represent
means  SEM or frequencies.
4. Results
4.1. Subjects
Control subjects and type 2 diabetes patients were matched
for age (58  1 and 59  1 year), body weight (86.7  3.1 and
89.4  1.5 kg) and BMI (27.3  0.9 and 28.8  0.4 kg/m2, respec-
tively; Table 1). HbA1c values were significantly higher in the
type 2 diabetes patients (7.5  0.1% [58  1 mmol/mol]) when
compared with the control subjects (5.6  0.1% [38  1 mmol/
mol]), respectively; P < 0.001). In addition, fasting plasma
glucose concentrations were significantly higher in the type 2
diabetes patients when compared with the healthy controls
Table 2 – Prevalence of hyperglycemia and glucose
concentrations.
Control
(n = 24)
Type 2
diabetes
(n = 60)
P value
Prevalence of hyperglycemia calculated over 3 periods, h:mm
24 h period 0:46  0:12 9:10  0:52 <0.001
Daytime 0:42  0:12 7:22  0:39 <0.001
Nocturnal 0:04  0:02 1:48  0:19 <0.001
Prevalence of hypoglycemia calculated over 3 period, h:mm
24 h period 2:02  0:50 0:22  0:08 0.057
Daytime 1:10  0:30 0:18  0:07 0.105
Nocturnal 0:52  0:21 0:04  0:02 0.032
Mean glucose concentrations calculated over 3 periods, mmol/L
24 h period 6.3  0.2 9.5  0.3 <0.001
Daytime 6.3  0.2 9.7  0.3 <0.001
Nocturnal 6.4  0.3 8.9  0.4 <0.001
Data are expressed as means  SEM. The prevalence of hypergly-
cemia and hypoglycemia are defined as total time glucose
concentrations were > 10 mmol/L and < 3.9 mmol/L, respectively.
Daytime period is calculated over an 18 h period (06:00 until 00:00).
Nocturnal period is calculated over a 6 h period (00:00 until 06:00).
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of insulin resistance in the type 2 diabetes patients when
compared with the control group (P < 0.001).
4.2. Blood glucose concentrations
The 24 h glycemic profiles recorded in both the type 2 diabetes
patients and healthy controls are illustrated in Fig. 1. Average
blood glucose concentrations throughout the 24 h period were
substantially higher in the type 2 diabetes patients compared
with the control subjects and averaged 9.5  0.3 and
6.3  0.2 mmol/L, respectively (P < 0.001; Table 2). Even the
diabetes patients with an HbA1c level below 7.0% (53 mmol/
mol; n = 20) showed average daily glucose concentrations that
were still markedly higher when compared with the normal
glucose tolerant control group (8.4  0.4 and 6.3  0.2 mmol/L,
respectively; P < 0.001). Hyperglycemic glucose excursions
following breakfast and lunch were largely responsible for
the higher average glucose concentration during daytime
(9.5  0.3 mmol/L) vs. nocturnal glucose concentrations
(8.9  0.3 mmol/L).
4.3. Prevalence of hyperglycemia
Type 2 diabetes patients experienced hyperglycemia for as
much as 38  4% of the day, representing a total duration of
9:10  0:54 h:mm per 24 h (Fig. 2A). In contrast, hyperglycemia
was negligible in the healthy control group (3  1%). In the
diabetes patients with an HbA1c content below 7.0% (53 mmol/
mol; n = 20) hyperglycemia was present 24  5% of the day
(5:50  1:06 h:mm), which was markedly higher compared
with the control group (P < 0.001) (Fig. 2B). As shown in Fig. 1,Time (h:mm )
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Fig. 1 – Average glucose concentrations over time in type 2
diabetes patients (n = 60; average 24 h glucose
concentration 9.5 W 0.3 mmol/L) and healthy,
normoglycemic, control subjects (n = 24; average 24 h
glucose concentration 6.3 W 0.2 mmol/L) under
standardized dietary, but otherwise free living conditions.
The upper and lower margins of the 95% CI are indicated
by the grey areas. Consumption of the main meals is
indicated by the vertical dashed lines.hyperglycemia following breakfast and lunch markedly
contributed to the greater prevalence of hyperglycemia during
daytime (7:22  0:39 h:mm) when compared with nocturnal
hyperglycemia (1:48  0:19 h:mm; Table 2).
4.4. Prevalence of hypoglycemia
Blood glucose levels below 3.9 mmol/L were regularly ob-
served during the day in normal glucose tolerant subjects
(2:02  0:50; Table 2). In comparison, hypoglycemia was
negligible in type 2 diabetes patients (0:22  0:08, P = 0.056).
There was no difference in the prevalence of hypoglycemia
between diabetes patients treated with insulin secretagogues
(i.e. SUDs) (0:14  0:07) and those treated with other blood
glucose lowering medication or diet only (0:32  0:07,
P = 0.271).
4.5. Relationship between HbA1c and daily glycemic
control
Overall, average 24 h blood glucose concentrations correlated
well with HbA1 levels (r = 0.73, P < 0.001). When calculated for
the diabetes and control group separately, the correlations
were r = 0.55 (P < 0.001) and r = 0.35 (P = 0.097), respectively. In
agreement, the daily prevalence of hyperglycemia correlated
well with HbA1c levels (r = 0.72; P < 0.001), whereas the
correlations for both groups separately were r = 0.57
(P < 0.001) and r = 0.05 (P = 0.796), respectively.
4.6. Relationship between hyperglycemia and insulin
sensitivity parameters
For the entire population, the prevalence of hyperglycemia
correlated well with HOMA-b% (r = 0.55, P < 0.001) and OGIS
(r = 0.63, P < 0.001), but not with HOMA-S% (r = 0.13,
P = 0.241). In the diabetes patients only, daily hyperglycemia
was related to HOMA-b% (r = 0.45, P < 0.001) and OGIS
(r = 0.44, P < 0.001), but not to HOMA-S% (r = 0.12,
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Fig. 2 – A: Daily prevalence of hyperglycemia (expressed as a percentage of the day that blood glucose concentrations exceed
10 mmol/L) in type 2 diabetes patients (n = 60, HbA1c 7.5 W 0.1% [58 W 1 mmol/mol]) compared with healthy, normoglycemic
controls. B: Daily prevalence of hyperglycemia (expressed as a percentage of the day that blood glucose concentrations
exceed 10 mmol/L) in well-controlled type 2 diabetes patients (n = 20, HbA1c <7.0% [<53 mmol/mol]) compared with healthy,
normoglycemic controls.
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were observed between hyperglycemia and HOMA or OGIS.
5. Discussion
The present study shows that hyperglycemia is highly
prevalent throughout the day in relatively well-controlled
type 2 diabetes patients receiving standard medical care. Type
2 diabetes patients experienced hyperglycemia more than 9 h
per day (over 24 h), assessed under strict dietary standardiza-
tion but otherwise free living conditions. Even those diabetes
patients with apparent good glycemic control (HbA1c below
7.0% [53 mmol/mol]) experienced excessive postprandial
hyperglycemia for nearly 6 h per day.
To improve our insight in the glycemic abnormalities
experienced by type 2 diabetes patients under normal free
living conditions, we assessed 24 h glycemic profiles in 60 type
2 diabetes patients and 24 healthy control subjects under strict
dietary standardization, but otherwise free living conditions
(Fig. 1). Despite the fact that the type 2 diabetes patients were
provided with a healthy diet based on their individual energy
requirements, and continued their use of oral blood glucose
lowering medication, hyperglycemia was experienced
throughout a remarkably large part of the day. In fact,
hyperglycemia was present for almost 40% of the entire
24 h period, representing more than 9 h per day (Fig. 2A). In
contrast, hyperglycemia was nearly non-existing in the
healthy, normal glucose tolerant control group. Furthermore,
it should be noted that the presented data on the prevalence of
hyperglycemia in the type 2 diabetes patients actually
represent an underestimate of the severity of the problem.
The prevalence of hyperglycemia would have been even morepronounced under (normal) conditions where habitual diet is
generally less balanced, with energy intake exceeding energy
expenditure. Remarkably, even when selecting patients with
HbA1c content below 7.0% (53 mmol/mol; n = 20), patients still
experienced hyperglycemia nearly 6 h per day (Fig. 2B). This
observation shows that HbA1c values below 7.0% (53 mmol/
mol) do not preclude the prevalence of excessive hyperglyce-
mia throughout the day, irrespective of the strong correlation
that was observed between HbA1c level and the daily duration
of hyperglycemic events (r = 0.72; P < 0.001).
The 24 h glycemic profiles of the type 2 diabetes patients
clearly show that hyperglycemia is primarily experienced
during postprandial conditions (Fig. 1). Despite the abundant
postprandial hyperglycemia experienced by type 2 diabetes
patients, postprandial blood glucose control is currently a
secondary target, when initial treatment fails to achieve target
HbA1c levels. The ADA and EASD guidelines explicitly state
that blood glucose management should focus on postprandial
hyperglycemia when HbA1c targets are not accomplished
[9,11]. However, the present study shows that even well-
controlled type 2 diabetes patients, achieving HbA1c target
values of below 7.0% (53 mmol/mol), experience substantial
levels of hyperglycemia throughout the day. Since postpran-
dial hyperglycemia significantly contributes to all-over gly-
cemic control, particularly in type 2 diabetes patients with
good HbA1c levels [4,5], blood glucose management in type 2
diabetes treatment should focus more on postprandial blood
glucose homeostasis independent of measured HbA1c values.
In line with previous observations [20,21], the present study
provides evidence that excessive hyperglycemia is most
pronounced during the morning following breakfast. This
observation has previously been described as the ‘‘extended
dawn phenomenon’’ [21] and is likely attributable to an
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leading to an uncontrolled rise in blood glucose following
breakfast. Standard treatment schemes with conventional
oral blood glucose lowering medication appear to have
insufficient therapeutic strength to normalize such postpran-
dial glucose increments. Targeted interventions with an
appropriate selection of therapeutic agents are warranted to
reduce postprandial hyperglycemia. The pharmaceutical
agents of interest include a-glucosidase inhibitors, glinides,
exogenous insulin, and incretin-based therapies [10]. Howev-
er, given the recent debate on the safety and effectiveness of
intensive glycemic treatment with glucose lowering medica-
tion [24], additional non-pharmacological approaches should
be advocated as well. In this regard, both dietary [25,26] as
exercise interventions [27,28] have proven most successful to
substantially reduce the prevalence of hyperglycemia
throughout the day.
In conclusion, postprandial hyperglycemia is a severely
underestimated problem in type 2 diabetes treatment. Even
well-controlled type 2 diabetes patients receiving standard
medical care experience excessive hyperglycemia (glucose
levels exceeding 10 mmol/L) throughout a substantial part of
the day. Obviously, standard medical care with conventional
oral blood glucose lowering medication or HbA1c levels below
7.0% (53 mmol/mol) do not preclude the prevalence of
excessive postprandial glucose excursions. More effective
pharmaceutical, nutrition and exercise intervention strategies
should be defined to further improve glycemic control in type 2
diabetes patients.
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